


Nizoral^{TRADEMARK}

(ketoconazole) (tablets)

over 3 million
prescriptions
world-wide:

the new beginning
in antifungal therapy.



Doctors and patients around the world are discovering the modern simplicity of Nizoral oral therapy. Common but problematic fungal infections

can now be treated effectively *and* conveniently. Typically, in recurrent *Candida* vaginitis, 2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem.



JANSSEN
PHARMACEUTICA

the drug discovery company

Prescribing Information

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole.

Uses: Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children, systemic mycoses and severe local infections where previous topical treatment has failed.

Side effects, precautions, contra-indications: contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole; these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances, gynecomastia has been reported.



Free to live a more active life

SURG

naprofen acid

potency in arthritis

The British Council International Medical Courses

THE CHILD AND INFECTION: RECOGNITION, MANAGEMENT AND PREVENTION

12-22 January 1986 in London

The purpose of this course is to provide an up-to-date review of practical problems concerning infections in infancy and childhood with regard to their prevention, diagnosis and treatment. Epidemiology, surveillance and the changing patterns of childhood infections in the community will be included.

Modern biological developments of gene identification, cloning and replication as tools for diagnosis, management and prevention of infections will be reviewed along with the role of the laboratory.

The course will be under the direction of **Dr W A M Cutting**, Senior Lecturer in Child Health, University of Edinburgh and **Professor H P Lambert**, Department of Communicable Diseases, St George's Hospital Medical School, University of London.

The course will be open to senior practising paediatricians and others involved in the diagnosis, treatment and control of infectious disease in individuals or children in the community.

There are vacancies for 30 participants.

Fee £695 (Residential), £450 (Non-residential).

The course sessions will take place at a hotel in Central London. Residential participants will be accommodated at the same hotel.

THE BIOLOGICAL BASIS OF RADIOTHERAPY

9-21 February 1986 in London

The course is designed for professors and heads of departments of radiotherapy and radiobiology, clinicians with a major interest in radiation oncology and pharmacologists working with radio-sensitizers and chemotherapy.

The course will be directed by **Professor G E Adams**, Director of the Medical Research Council Radiobiology Unit and **Professor M J Peckham** of the Institute of Cancer Research, University of London and the Royal Marsden Hospitals.

There are vacancies for 35 participants.

Fee £795 (Residential), £515 (Non-residential).

The course sessions will be held at an hotel in London. Residential participants will be accommodated at the same hotel.

BONE MARROW TRANSPLANTATION: SEMINARS ON RECENT ADVANCES

16-21 March 1986 in London

The course will present a perspective of the British experience so far and discuss future developments, both organisational and scientific. The Director of Studies will be **Dr E C Gordon-Smith**, Reader in Haematology, Royal Postgraduate Medical School, University of London.

The course will visit different transplantation centres in London where appropriate symposia will take place. The course is intended for consultants and other senior staff with an academic interest in bone marrow transplantation.

There are vacancies for 30 participants.

Fee £450 (Residential), £290 (Non-residential).

Residential participants will be accommodated at a hotel in Central London.

ALCOHOLISM AND DRUG DEPENDENCE: A MULTIDISCIPLINARY INTERNATIONAL SEMINAR

6-18 April 1986 in London

The focus will include alcohol, illicit drugs, psychotropic substances and nicotine.

The seminar will be based at the Institute of Psychiatry in London. The Director of Studies will be **Professor Griffith Edwards**, Professor of Addiction Behaviour in the University of London and Director of the Addiction Research Unit at the Institute of Psychiatry, University of London. Dependence problems are of relevance to many disciplines. The seminar aims to attract a very wide representation of those who deal with these issues, either clinically, at the level of policy and organisation, as educationalists or in research.

There are vacancies for 30 participants.

Fee £795 (Residential), £515 (Non-residential).

Residential participants will be accommodated at a hotel in Central London.

FURTHER INFORMATION AND APPLICATION FORMS CAN BE OBTAINED FROM YOUR LOCAL OVERSEAS REPRESENTATIVE OF THE BRITISH COUNCIL OR FROM COURSES DEPARTMENT, THE BRITISH COUNCIL, 65 DAVIES STREET, LONDON W1Y 2AA.

APPROPRIATE TECHNOLOGY

Many of the difficulties of Third World medicine—the effects of poverty, starvation, overpopulation, and political unrest—are beyond the individual doctor's control; but what the Western trained doctor practising in the developing world can and must do is to adapt his practice to compensate for the absence of sophisticated equipment, trained staff, and expensive drugs. Written by doctors and technicians with first hand experience of the problems, *Appropriate Technology* is a guide to the sensible choice and use of resources.

The British Medical Journal has subsidised this title to make this information widely available at as low cost as possible.

Price: Inland £2.50; Abroad £5.00/USA \$8.00
BMA members (please quote membership number):
Inland £2.00; Abroad £4.50/USA \$7.00

Despatched by air overseas

Payment must be enclosed with order

Order your copy now

From: The Publishing Manager, British Medical Journal,
BMA House, Tavistock Square, London WC1H 9JR
or any leading bookseller

THE MRCP CORRESPONDENCE COURSE IN INTERNAL MEDICINE

- *Continually updated**
- *New clinical slides**
- *Includes X-rays and ECG's**
- *Essential for Part I and Part II**

Write for full information to:
J. ARNOLD Dept 5
(Correspondence Courses)
19, VILLAGE WAY,
LONDON SE21 7AN

HOW TO DO IT

SECOND EDITION

The first edition of HOW TO DO IT proved a useful and popular guide to those things a doctor needs to know but is rarely taught: how to take an examination, how to interview and be interviewed, how to plan and write up research, how to behave at an inquest. In the second edition the original chapters have been expanded and updated, and there are several more chapters on new challenges—choosing a computer, flying, holding a press conference—and on some older ones not included in the first edition—assessing a job, dealing with a publisher.

Price: Inland £6.50
Abroad £9.00/USA\$14.50
BMA members: Inland £6.00
Abroad £8.50/USA\$13.50
including postage, by air abroad

Please quote
membership number

**Payment must be enclosed
with order**

Order from
The Publishing Manager
British Medical Journal
BMA House, Tavistock Square
London WC1H 9JR
or any leading bookseller

ADALAT® RETARD: ANTIHYPERTENSIVE WITH CARDIOPROTECTIVE EFFECT

Long term therapy with Adalat retard

- reduction in peripheral vascular resistance
- reduction in high blood pressure (reliable reduction in pathologically high blood pressure)
- permanent relief of the heart
- improvement of the myocardial oxygen balance
- protection of cell against unphysiological noxious Ca^{++} concentrations in case of a pathological ion overflow.

E 4/042

THE MODERN COMPREHENSIVE DRUG THERAPY OF CARDIOVASCULAR DISEASE: ADALAT RETARD.

Composition: 1 tablet Adalat® retard contains 20 mg nifedipine. **Indications:** Coronary heart disease: Early and long-term treatment of coronary heart disease (in particular coronary insufficiency, angina pectoris, post-infarction syndrome). All forms of hypertension. **Contraindication:** Pregnancy. **Side effects:** Side effects occur only rarely and, if at all, at the beginning of treatment; they are usually mild and transient. Occasional symptoms may be headache, facial flush and heat sensation, leg oedema, nausea, dizziness, tiredness and skin reactions. As is the case with other vasoactive substances, chest pain may very occasionally occur after administration. In this event Adalat should be discontinued if the pains are considered to have been caused by the medication. **Interactions:** Adalat can be administered together with antihypertensive agents, however, the additive effect should be taken into account. Treatment with cardiac glycosides can be begun or continued during nifedipine treatment. A combination treatment of Adalat retard with beta blockers or a saluretic is possible (see S.M.L.). **Dosage:** Treatment should be adjusted individually to the degree of severity of the disease and to the patient's responsiveness. A daily dose of 2 x 1 tablet of Adalat retard (2 x 20 mg) is recommended. In individual cases an increase in the daily dose to 2 x 2 tablets of Adalat retard (2 x 40 mg) may be necessary. The recommended interval between tablet intake is about 12 hours and should not be shorter than 4 hours. Generally, the tablet is swallowed unchewed with a little liquid, independent of meals. **Note:** In the presence of coronary spasms (Prinzmetal angina, angina at rest) and particularly severe forms of coronary heart disease or in the case of impending anginal attack or acute hypertensive crisis which all require a quick onset of effect, Adalat capsules which are marked by rapid action should be taken chewed. When the patient's condition has improved, a change-over to Adalat retard tablets may be attempted. **Presentation:** Tablets of 20 mg Nifedipine. Box of 30 tablets, box of 50 tablets, box of 100 tablets, hospital size pack.

ADALAT

ANTIHYPERTENSIVE
WITH CARDIOPROTECTIVE EFFECT

Bayer Germany

